Ultra 96+:Ultra-High-Throughput Antibody Production Services

ariation in 96 DWP

The Average Titer and Recovery Rate of Ultra 96+ Platform The left histogram shows the average titer of mAb and Fc fusion protein production using the Ultra 96+ platform. High-titer production was accomplished with both types of antibodies in the 96 DWP at 1 mL culture volume. The graphs show an average recovery rate of 83% or more was achieved in both 1 mL culture using 96 DWP and 3 mL culture using 24 DWP. 1503

Recovery Rate (24 DWP)

Average 84%

90%

80%

70%

60%

50%

Titer Variation in 96 DWP

1 2 3 4 5 6 7 8 9 101112131415161718192021222324

Recovery Rate (24 DWP)

969

Average 84%

90%

1503

50% 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96 DWP) Average 83% 60% 80% 1 2 3 4 5 6 7 8 9 101112131415161718192021222324 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96 DWP) Average 83%

Need original image 70%

595

1013

969

mAb

Bispecific

Fc fusion

Control

mAb

Fc fusion

Case Study: WuXian TM uHTP Platform

The Ultra 96+ platform incorporates an ultra-high titer transient CHO expression system that significantly enhances titers and overall yields. In this case study, the Ultra 96+ platform showcases remarkable mean final yield of antibody drug molecules in 1 mL culture using 96-DWP, achieving 1.2 mg for 960 antibodies, 0.98 mg for 536 VHH-Fc, 0.55 mg for 557 Fab, and 0.3 mg for 100 His-VHH. The proteins are suitable for in vitro assays.

960 Antibodies

100 His-VHH

536 VHH-Fc

557 Flag-FABs

0 0.3 0.6 0.9 1.2 1.5 1.8 2.1

2

0.6

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9

0.5

1.5

0.55 mg

0.4

1.2 mg

0.98 mg

0.3 mg

1

0.3

0.2

0.5

0.1

0

0

96 Well DWP (1 mL/well)

Learn more: Protein Sciences: uHTP Antibody Production

About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world’s leading global single-source platform from concept to commercialization.

wuxibiologics.com | info@wuxibiologics.com

5-9-2024

Powered by